How do I buy Biomea Fusion, Inc. Common Stock (BMEA) stock?

Buying Biomea Fusion, Inc. Common Stock (BMEA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "BMEA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy BMEA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for BMEA on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Biomea Fusion, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Biomea Fusion, Inc. Common Stock (BMEA) pay dividends?

At the moment, Biomea Fusion, Inc. Common Stock (BMEA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track BMEA's performance via the price chart in the Gotrade app.

Is buying BMEA on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy BMEA?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if BMEA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Biomea Fusion, Inc. Common Stock (BMEA) Stock Price Today & Analysis

% positive news of 6 articles

published over the past 14 days

Latest news

Zacks Investment Research

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

NeutralBMEASeptember 4, 2026

Zacks Investment ResearchNeutral

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

BMEA

Benzinga

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

NeutralBMEAJune 11, 2024

BenzingaNeutral

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

BMEA

InvestorPlace

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

NeutralBMEAJune 6, 2024

InvestorPlaceNeutral

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

BMEA

Finbold

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

NeutralBMEADecember 29, 2023

BarronsNeutral

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

BMEA

About Biomea Fusion, Inc. Common Stock

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

SectorHealthcare

IndustryBiotechnology

Employees37

CEODr. Michael J. M. Hitchcock Ph.D.

IPO DateApr 15, 2021

HeadquartersSan Carlos, CA

Key Executives

Name	Title	Year Born
Dr. Michael J. M. Hitchcock Ph.D.	Interim CEO & Director	1950
Mr. Ramses M. Erdtmann	Co-Founder, President, COO & Director	1963
Mr. Heow Tan	Chief Technical & Quality Officer	1959
Caroline Perez- Dupont J.D.	Senior Vice President of Legal	—
Dr. Thorsten Kirschberg Ph.D.	Executive Vice President of Research	1970
Dr. Stephan Morris M.D.	Chief Development Officer	—
Mr. Ravi Upasani Ph.D.	Executive Vice President of Intellectual Property	—

Fundamentals

Valuation

Market cap$95.68M

Price-to-sales ratioN/A

Price-to-book value8.90

Price-earnings ratio-3.30

Return on Equity-197.00%

Return on SalesN/A

Return on Assets-77.00%

PEG ratioN/A

Earnings Per Share

Earnings Per Share$-0.29

Income Statement

Average volume2,391,114

EBITDA$-42.88M

1 year high (52w)$2.99

1 year low (52w)$0.87

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsSell5 Indicators

Moving AveragesStrong Sell12 Indicators

What the experts say

0 Wall Street Analyst Ratings

N/A

0% Buy

0% Hold

0% Sell

Target price

$0.00

Est return

0.00%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026				-30.3	+0.7	+5.8	-14.0	+40.0	-26.7

Biomea Fusion, Inc. Common Stock (BMEA) Stock

Fundamentals

Recent news

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

Looking for the next meme stock? These stocks are short-squeeze targets

Looking for the next meme stock? These stocks are short-squeeze targets

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

Looking for the next meme stock? These stocks are short-squeeze targets

Looking for the next meme stock? These stocks are short-squeeze targets

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

About Biomea Fusion, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade